Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ADMS NASDAQ:CALT NYSE:MBX NYSE:ZYME On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeADMSAdamas Pharmaceuticals$8.22$8.17$4.02▼$9.15$376.37M2.82692,487 shsN/ACALTCalliditas Therapeutics AB (publ)$40.00$40.00$15.25▼$43.00$1.19B1.7710,339 shsN/AMBXMBX Biosciences$15.09+5.7%$12.95$4.81▼$27.50$506.93MN/A324,882 shs154,165 shsZYMEZymeworks$14.81-0.2%$13.40$9.03▼$17.70$1.11B1.26526,977 shs314,217 shs The Best Nuclear Energy Stocks to BuyNuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceADMSAdamas Pharmaceuticals0.00%0.00%0.00%0.00%0.00%CALTCalliditas Therapeutics AB (publ)0.00%0.00%0.00%0.00%-1.23%MBXMBX Biosciences-0.28%+0.85%-4.61%+13.89%+1,426,999,900.00%ZYMEZymeworks-0.60%+3.13%+9.84%+27.16%+30.40%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationADMSAdamas PharmaceuticalsN/AN/AN/AN/AN/AN/AN/AN/ACALTCalliditas Therapeutics AB (publ)N/AN/AN/AN/AN/AN/AN/AN/AMBXMBX Biosciences2.6883 of 5 stars3.50.00.00.03.41.70.6ZYMEZymeworks2.2712 of 5 stars3.50.00.00.03.71.70.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceADMSAdamas Pharmaceuticals 0.00N/AN/AN/ACALTCalliditas Therapeutics AB (publ) 0.00N/AN/AN/AMBXMBX Biosciences 3.00Buy$37.63149.34% UpsideZYMEZymeworks 2.90Moderate Buy$21.4344.69% UpsideCurrent Analyst Ratings BreakdownLatest ADMS, CALT, ZYME, and MBX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails8/11/2025ZYMEZymeworksCitigroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$19.00 ➝ $22.008/5/2025MBXMBX BiosciencesMizuhoSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOutperform$38.007/16/2025MBXMBX BiosciencesOppenheimerSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOutperform$38.007/3/2025ZYMEZymeworksHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingNeutral ➝ Neutral$13.00(Data available from 8/29/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookADMSAdamas Pharmaceuticals$74.46M5.05N/AN/A($0.47) per share-17.49CALTCalliditas Therapeutics AB (publ)$1.60B0.74N/AN/A$1.06 per share37.74MBXMBX BiosciencesN/AN/AN/AN/AN/AN/AZYMEZymeworks$122.87M9.06N/AN/A$6.63 per share2.23Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateADMSAdamas Pharmaceuticals-$57.40M-$1.70N/AN/AN/A-71.11%N/A-42.96%N/ACALTCalliditas Therapeutics AB (publ)-$43.96M-$1.85N/A8.68N/A-30.18%-212.04%-27.96%N/AMBXMBX BiosciencesN/A-$4.54N/AN/AN/AN/AN/AN/AN/AZYMEZymeworks-$118.67M-$0.97N/AN/AN/A-182.75%-23.00%-18.04%10/30/2025 (Estimated)Latest ADMS, CALT, ZYME, and MBX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/7/2025N/AZYMEZymeworks-$0.52$0.03+$0.55N/A$17.18 million$48.73 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthADMSAdamas PharmaceuticalsN/AN/AN/AN/AN/ACALTCalliditas Therapeutics AB (publ)N/AN/AN/AN/AN/AMBXMBX BiosciencesN/AN/AN/AN/AN/AZYMEZymeworksN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioADMSAdamas Pharmaceuticals21.254.534.17CALTCalliditas Therapeutics AB (publ)9.442.692.59MBXMBX BiosciencesN/AN/AN/AZYMEZymeworksN/A4.104.10Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipADMSAdamas Pharmaceuticals69.97%CALTCalliditas Therapeutics AB (publ)2.83%MBXMBX BiosciencesN/AZYMEZymeworks92.89%Insider OwnershipCompanyInsider OwnershipADMSAdamas Pharmaceuticals18.90%CALTCalliditas Therapeutics AB (publ)2.20%MBXMBX Biosciences52.19%ZYMEZymeworks1.92%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableADMSAdamas Pharmaceuticals13845.79 million37.13 millionOptionableCALTCalliditas Therapeutics AB (publ)18029.79 million29.14 millionOptionableMBXMBX Biosciences3633.59 millionN/AN/AZYMEZymeworks46075.17 million67.56 millionOptionableADMS, CALT, ZYME, and MBX HeadlinesRecent News About These CompaniesZymeworks Reports Q2 Results and FDA ClearanceAugust 19, 2025 | theglobeandmail.comZymeworks Announces Participation in Upcoming Investor ConferencesAugust 19, 2025 | globenewswire.comZymeworks Inc. (NYSE:ZYME) Shares Purchased by Tejara Capital LtdAugust 17, 2025 | marketbeat.comZymeworks Earnings Call: Revenue Surge and Strategic GainsAugust 13, 2025 | msn.comZymeworks (ZYME) Could Find a Support Soon, Here's Why You Should Buy the Stock NowAugust 12, 2025 | zacks.comCitigroup Raises Zymeworks (NYSE:ZYME) Price Target to $22.00August 12, 2025 | marketbeat.comQ1 Earnings Estimate for Zymeworks Issued By Lifesci CapitalAugust 12, 2025 | marketbeat.comZymeworks Inc.: Zymeworks Strengthens Board of Directors with Appointments of Greg Ciongoli and Robert E. LandryAugust 11, 2025 | finanznachrichten.deZymeworks Strengthens Leadership with New Board AppointmentsAugust 11, 2025 | tipranks.comZymeworks Inc. Appoints Greg Ciongoli and Robert E. Landry to Board of DirectorsAugust 11, 2025 | quiverquant.comQZymeworks Strengthens Board of Directors with Appointments of Greg Ciongoli and Robert E. LandryAugust 11, 2025 | financialpost.comFZymeworks Strengthens Board of Directors with Appointments of Greg Ciongoli and Robert E. LandryAugust 11, 2025 | globenewswire.comZymeworks Inc. (NYSE:ZYME) Receives Average Rating of "Moderate Buy" from AnalystsAugust 11, 2025 | marketbeat.comEarnings Beat: Zymeworks Inc. Just Beat Analyst Forecasts, And Analysts Have Been Updating Their ModelsAugust 10, 2025 | finance.yahoo.comZymeworks (NYSE:ZYME) Announces Earnings Results, Beats Expectations By $0.55 EPSAugust 9, 2025 | marketbeat.comZymeworks signals expanded royalty streams and milestone-driven cash infusions through new approvals and pipeline progressionAugust 8, 2025 | msn.comZymeworks Inc. (ZYME) Q2 2025 Earnings Call TranscriptAugust 8, 2025 | seekingalpha.comZymeworks Inc. (ZYME) Tops Q2 Earnings and Revenue EstimatesAugust 7, 2025 | zacks.comZymeworks Provides Corporate Update and Reports Second Quarter 2025 Financial ResultsAugust 7, 2025 | globenewswire.comZymeworks (ZYME) Projected to Post Earnings on ThursdayJuly 31, 2025 | marketbeat.comBispecific Antibodies Market Report 2025- 2035, with Profiles of Akeso Biopharma, Alexion, Amgen, Genmab, Immunocore, Linton Pharm, Merck, OncXerna Therapeutics, Zymeworks, and ...July 30, 2025 | finance.yahoo.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeADMS, CALT, ZYME, and MBX Company DescriptionsAdamas Pharmaceuticals NASDAQ:ADMSAdamas Pharmaceuticals, Inc. engages in discovery and development of chrono-synchronous therapies for chronic neurologic disorders. Its products include GOCOVRI, ADS-5012, ADS-4101, and Namzaric. GOCOVRI is indicated for the treatment of dyskinesia in patients with Parkinson's disease receiving levodopa-based therapy. ADS-5102 is a treatment for walking impairment in patients with multiple sclerosis. ADS-401 treats partial onset seizures in patients with epilepsy. Namzaric is a drug treatment for moderate to severe Alzheimer's disease. The company was founded by Gregory T. Went on November 15, 2000 and is headquartered in Emeryville, CA.Calliditas Therapeutics AB (publ) NASDAQ:CALT$40.00 0.00 (0.00%) As of 08/28/2025Calliditas Therapeutics AB (publ), a commercial-stage bio-pharmaceutical company, focused on identifying, developing, and commercializing novel treatments in orphan indications with an initial focus on renal and hepatic diseases with significant unmet medical needs in the United States, Europe, and Asia. It offers Nefecon (TARPEYO/Kinpeygo), an oral formulation of budesonide to reduce the loss of kidney function in adults with immunoglobulin A nephropathy. The company's lead compound is Setanaxib, a NOX inhibitor that is in Phase 2b clinical trial for the treatment of primary biliary cholangitis; and in Phase 2 clinical trial for the treatment of squamous cell carcinoma of the head and neck cancer and idiopathic pulmonary fibrosis, as well as for solid tumors and Alport Syndrome. Calliditas Therapeutics AB (publ) was incorporated in 2004 and is headquartered in Stockholm, Sweden.MBX Biosciences NYSE:MBX$15.09 +0.82 (+5.75%) Closing price 04:00 PM EasternExtended Trading$15.04 -0.05 (-0.33%) As of 04:20 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.MBX Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of precision peptide therapies for the treatment of endocrine and metabolic disorders. Its lead product candidate is MBX 2109, a parathyroid hormone peptide prodrug, which is in Phase 2 clinical trial designed as a potential long-acting hormone replacement therapy for the treatment of chronic hypoparathyroidism. The company is also developing MBX 1416, a long-acting glucagon-like peptide-1 (GLP-1) receptor antagonist that is in Phase 1 clinical trial designed as a potential therapy for post-bariatric hypoglycemia, a chronic complication of bariatric surgery. In addition, it is developing MBX 4291, a lead obesity product candidate, which is in investigational new drug-enabling studies designed as a long-acting and highly potent GLP-1 and glucose-dependent insulinotropic polypeptide receptor co-agonist prodrug for treating obesity and co-morbidities. The company was founded in 2018 and is based in Carmel, Indiana.Zymeworks NYSE:ZYME$14.81 -0.03 (-0.20%) Closing price 04:00 PM EasternExtended Trading$14.81 0.00 (0.00%) As of 05:38 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Zymeworks Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes biotherapeutics for the treatment of cancer. The company's lead product candidates include zanidatamab, a human epidermal growth factor receptor 2 (HER2) that is in Phase 1, Phase 2, and Phase 3 clinical trials, including certain ongoing pivotal clinical trials; and zanidatamab zovodotin, a HER2 -targeted antibody-drug conjugate that is in Phase 2 clinical trial for the treatment of advanced or metastatic HER2-expressing tumors. It also develops a pipeline of preclinical product candidates and discovery-stage programs in oncology, including immuno-oncology agents and other therapeutic areas. Zymeworks Inc. has strategic partnerships and collaborations with BeiGene, Ltd.; Celgene Corporation; Celgene Alpine Investment Co. LLC; GlaxoSmithKline Intellectual Property Development Limited; Daiichi Sankyo Co., Ltd.; Janssen Biotech, Inc.; LEO Pharma A/S; Iconic Therapeutics, Inc.; Merck Sharp & Dohme Research GmbH; and Atreca, Inc. Zymeworks Inc. was incorporated in 2003 and is based in Middletown, Delaware. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Ollie’s Bargain Outlet: Buy it While It’s Still a Bargain Best Buy Marketplace: Potential Growth Catalyst or Risky Gimmick? CrowdStrike at a Crossroads: AI Halo vs. Risks Snowflake’s Snowballing Business and Robust Stock Price Outlook NVIDIA's Earnings Show a Green Light for Taiwan Semiconductor NVIDIA Stock Could Pull Back in September, But Don’t Bet on It 3 Reasons Gartner Could Be the Best Buy of Q3 NIO Just Got Its Second Upgrade of the Month, and It’s Big Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access